Key result
Weekly paclitaxel induced complete remission in two patients with locally recurrent secondary breast angiosarcoma, with rapid re-induction of remission upon drug resumption after treatment delays.
Why the study?
Does weekly paclitaxel induce prolonged disease control in patients with secondary breast angiosarcoma?
Case Report (n=2)
Does weekly paclitaxel induce prolonged disease control in patients with secondary breast angiosarcoma?
Weekly paclitaxel can induce complete remission and prolonged disease control in secondary breast angiosarcoma, even after treatment interruptions.
May support paclitaxel in recurrent secondary breast angiosarcoma; leaves open efficacy and durability in prospective trials.
Secondary breast angiosarcomas are a well-known entity generally characterized by a poor outcome, especially in patients with advanced disease. Among the drugs with demonstrated activity, taxane derivatives are one of the most effective histology-driven treatments against angiosarcomas. We report two cases of secondary breast angiosarcoma, both characterized by a very peculiar behavior towards paclitaxel. Both patients showed local recurrence of angiosarcoma after primary surgery, and they achieved complete remission following treatment with weekly paclitaxel. When a locoregional recurrence was observed as a result of a brief treatment interruption or a treatment delay, a new complete remission was rapidly achieved with the resumption of the drug, without evidence of any significant adverse effects.
No takes yet. Share an insight, caveat, or question.
Gambini et al. (2015) conducted a case report in Secondary breast angiosarcoma (n=2). Paclitaxel was evaluated on Complete remission. Weekly paclitaxel induced complete remission in two patients with locally recurrent secondary breast angiosarcoma, with rapid re-induction of remission upon drug resumption after treatment delays.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: